Propanc 10-K: Going Concern, Material Weaknesses, and $18.9M Loss
PPCB sits 16% above its 52-week low of $0.56 on light trading volume (0.1× avg).
Summary
Propanc Biopharma's FY2026 10-K reveals a going concern warning, material weaknesses in financial controls, and a $18.9M net loss. The Series C preferred stock conversion terms could severely dilute existing shareholders.
Key Events · Earnings and Guidance · PPCB
-
Going Concern Qualification
Auditor Salberg & Company included a going concern qualification for FY2026. Net loss was $18.86M, net cash used in operations was $5.68M, and accumulated deficit reached $144.48M.
-
Material Weaknesses in Internal Controls
Management disclosed material weaknesses: no written documentation of internal control policies and insufficient segregation of duties within accounting functions.
-
Series C Preferred Stock Dilution Risk
Series C Preferred Stock converts at the lesser of $125.00 fixed price or 85% of lowest trading price, with floor price reset to $0.05 after the May 2026 reverse split. 200 shares outstanding with $2M redemption value.
-
Subsequent Events: Heavy Stock Issuance
After June 30, 2026, the company issued 3.5M shares for services valued at $4.795M, converted 2.2M shares from Series C preferred, and repurchased 320,031 shares for $500K.
Analysis · PPCB · Life Sciences
The annual report confirms the company's precarious financial position. The auditor's going concern qualification, $18.9M net loss, and $144.5M accumulated deficit show the company cannot fund operations without new capital. Material weaknesses in internal controls add governance risk. The Series C preferred stock conversion terms, with a floor price reset to $0.05, create massive potential dilution for common shareholders. Subsequent events show continued heavy stock-based compensation and share repurchases that appear contradictory.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPCB was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.56 to $52.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.